FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 356:2525-2526 June 14, 2007 Number 24 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Reboli, A. C. Related Article by Manzoni, P. PubMed Citation

For three decades, antifungal chemotherapy was dominated by a single effective fungicidal agent: amphotericin B deoxycholate. However, concern about toxicity profoundly limited its use. The 1990s saw the introduction of the triazoles, such as fluconazole, and although these drugs were not more effective than amphotericin, their safety profile allowed their clinical use as prophylactic and empirical agents. As fear of their toxic effects subsided, inappropriate and unvalidated use appeared — and as expected, acquired microbial resistance emerged as an important issue.

The newest class of antifungal agents was heralded by the approval of caspofungin for candidiasis in 2002, and already . . . [Full Text of this Article]

Source Information

From the Division of Infectious Diseases, Department of Internal Medicine, Wayne State University School of Medicine, Detroit.

This article has been cited by other articles:

• (2007). Anidulafungin vs. Fluconazole for Invasive Candidiasis. JWatch Infect. Diseases 2007: 1-1 [Full Text]